Loading patent…
AssigneeSubsidiary No. 3, Inc.
InventorsTanya A. Holzmayer, Stephen J. Dunn, Andrew Dayn
Estimating the term…
The present invention relates to the identification of a number of human genes as cellular targets for the design of therapeutic agents for suppressing human immunodeficiency virus infection. These genes encode products which appear to be necessary for HIV replication, as evidenced by an inhibition of HIV infection in cells in which the expression of these genes is down-regulated. In addition, the invention also relates to methods for identifying additional cellular genes as therapeutic targets for suppressing HIV infection, and methods of using such cellular genes and their encoded products in screening assays for selecting additional inhibitors of HIV.
An HIV inhibitory composition, comprising an isolated polynucleotide corresponding to a portion of a cellular gene or a complement thereof, said gene encodes an intracellular product which is necessary for a productive HIV infection, said polynucleotide is operably linked to a regulatory sequence, and expression of said polynucleotide in a host cell inhibits infection by HIV.
An HIV inhibitory composition, comprising an isolated polynucleotide corresponding to a portion of a gene encoding human CD44 or a complement thereof, said polynucleotide is operably linked to a regulatory sequence and expression of said polynucleotide in a host cell inhibits infection by HIV.
A method for identifying a cellular gene which encodes a product necessary for HIV infection, comprising:
A method for inhibiting HIV infection, comprising administering a therapeutically effective amount of an inhibitor of a cellular gene to an individual to inhibit HIV infection.
A method for selecting HIV an inhibitor, comprising:
Dependencies are inferred from the claim text.